Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily.
The CD85 molecule was originally defined at the Fifth Workshop on Leucocyte Antigens in 1993 by two monoclonal antibodies, VMP55 and GHI/75. This cell-surface glycoprotein is expressed on B cells, monocytes, and subpopulations of T and natural killer (NK) cells, and particularly high levels are expressed by normal and neoplastic plasma cells and by hairy cell leukemia B cells. We affinity purified the CD85 antigen and obtained tryptic peptide sequence which indicated that this molecule might be ILT2, a recently described inhibitory major histocompatibility complex class I receptor of the immunoglobulin superfamily. This was confirmed by showing that both of the original anti-CD85 mAbs stained ILT2 transfectants. The cell signaling role demonstrated for ILT2 is consistent with the previously reported involvement of CD85 in T cell activation.
Banham
A H
AH
University of Oxford, Nuffield Department of Clinical Biochemistry and Cellular Science, John Radcliffe Hospital, Headington, United Kingdom. abanham@worf.molbiol.ox.ac.uk
Colonna
M
M
Cella
M
M
Micklem
K J
KJ
Pulford
K
K
Willis
A C
AC
Mason
D Y
DY
D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000737:chemistry* / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D000075362:Leukocyte Immunoglobulin-like Receptor B1; D011971:Receptors, Immunologic / Q000737:chemistry* / Q000276:immunology; D017386:Sequence Homology, Amino Acid
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C105299:LILRB1 protein, human; D000075362:Leukocyte Immunoglobulin-like Receptor B1; D011971:Receptors, Immunologic